Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

IMCR - Immunocore Holdings plc So'nggi... | Finranks

Home

/

IMCR

I

Immunocore Holdings plc (IMCR)

NMS – Real vaqt narxi. Valyuta: USD

34.44

+0.26 (0.76%)

Bozor ochiq: Aug 12, 2026, 3:16 PM EDT

34.86

+0.68 (1.99%)

Oldingi bozordan keyin: Aug 11, 2026, 7:56 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum

IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum

Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.

Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?

Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?

Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.

IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss

IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss

Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.

Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues

Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues

IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.

Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 77.9% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript

Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript

Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript

Immunocore Q2 Earnings Call Highlights

Immunocore Q2 Earnings Call Highlights

Immunocore NASDAQ: IMCR reported continued growth for KIMMTRAK in the second quarter and first half of 2026, while advancing three late-stage melanoma trials and early-stage programs in oncology, HIV and Type 1 diabetes.

Videolar

No Data

There is no data to display

Press-relizlar

Immunocore reports second quarter financial results and provides a business update

Immunocore reports second quarter financial results and provides a business update

Immunocore reports second quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma nearing the target of 540 patients – Data could come as early as end of 2026 Oral presentation of five-year overall survival data showing KIMMTRAK doubles likelihood of being alive at five years for patients with HLA-A*02:01 positive metastatic uveal melanoma Promising Phase 1 brenetafusp monotherapy clinical activity in heavily pretreated HLA-A*02:01-positive patients with advanced melanoma, presented at ASCO, supports selected dose for Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma Cash, cash equivalents and marketable securities of $880 million as of June 30, 2026 Conference call today, August 6 at 8:00 AM ET, 1:00 PM BST (OXFORDSHIRE, England & RADNOR, PA. & GAITHERSBURG, MD.